Intervention not reported
Infection‐ related mortality
The intervention showed no clear difference in infection‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Second cancer‐ related mortality
The intervention showed no clear difference in second cancer‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Cardiac disease‐ related mortality
The intervention showed no clear difference in cardiac disease‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Complete response rate
The intervention showed no clear difference in complete response rate (low certainty).
1 finding from 1 review
Intervention not reported
Mortality (calculated instead of overall survival)
The intervention may leads to higher mortality (calculated instead of overall survival) (low certainty).
1 finding from 1 review
Intervention not reported
Relapse, progression or death (calculated instead of PFS)
The intervention showed no clear difference in relapse, progression or death (calculated instead of PFS) (low certainty).
1 finding from 1 review
Intervention not reported
Relapses/death (instead of disease‐free survival）[2] · People with AML in first complete remission
The intervention showed no clear difference in relapses/death (instead of disease‐free survival）[2] (low certainty).
1 finding from 1 review
Intervention not reported
Mortality (instead of overall survival)[2] · People with AML in first complete remission
The intervention showed no clear difference in mortality (instead of overall survival)[2] (moderate certainty).
1 finding from 1 review
Intervention not reported
Death/progress (instead of event‐free survival)[2] · People with AML in first complete remission
The intervention showed no clear difference in death/progress (instead of event‐free survival)[2] (low certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality · People with AML in first complete remission
1 finding from 1 review
Intervention not reported
Adverse events: hypersensitivity · People with AML in first complete remission
It is very uncertain whether the intervention changes adverse events: hypersensitivity (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: fatigue · People with AML in first complete remission
It is very uncertain whether the intervention changes adverse events: fatigue (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: rigor/chills · People with AML in first complete remission
It is very uncertain whether the intervention changes adverse events: rigor/chills (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: arthralgia/myalgia · People with AML in first complete remission
It is very uncertain whether the intervention changes adverse events: arthralgia/myalgia (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life · People with AML in first complete remission
1 finding from 1 review
Intervention not reported
Mortality at 2 years · patients with newly diagnosed AML
The intervention leads to lower mortality at 2 years (high certainty).
1 finding from 1 review
Intervention not reported
Complete remission · patients with newly diagnosed AML
The intervention showed no clear difference in complete remission (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse · patients with newly diagnosed AML
The intervention showed no clear difference in relapse (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 3/4 cardiotoxicity · patients with newly diagnosed AML
The intervention showed no clear difference in grade 3/4 cardiotoxicity (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life not reported · patients with newly diagnosed AML
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported